From the editor

Article

Happy New Year to you all and welcome to the second edition of Ophthalmology Times Europe.

This issue sees us ask the question "Will phakic IOL implantation become the procedure of choice for certain forms of refractive correction?" Some experts believe so and this month we are fortunate enough to relay to you the opinions, knowledge and experience of several refractive specialists. With each tackling various issues relating to phakic IOL use, is the evidence presented here compelling enough for you to tout the new generation of refractive lenses as a force to be reckoned with? Could you convince your patients to accept this form of refractive correction, despite current perceptions? Read on and form your own opinions.

Elsewhere, we focus on advances in the ever-changing area of corneal surgery. Massimo Busin describes a new method of microkeratome-assisted penetrating keratoplasty that does not require endothelial transplantation for advanced keratoconus - a study that gained him an award for a "Best National Paper on Ophthalmology" from the World Ophthalmology Congress 2006. Meanwhile, Daljit Singh describes a new method, which could eliminate the need for corneal transplants in certain cases. Also in this issue, we present some recent advances and cutting edge discoveries in the areas of cataract surgery and glaucoma treatment, designed to intrigue and enthuse you.

As always, I would be delighted to hear what you have to say so please do let me know what you think of Ophthalmology Times Europe, what you like, what you don't like and, most importantly, how we can serve you better. Why not stop by at the World Ophthalmology Congress in SãPaulo and speak with us personally. Alternatively, please direct any feedback to [email protected]

I look forward to hearing from you.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.